Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma

Moriya,Makio; Yamada,Tadaaki; Tamura,Masaya; Ishikawa,Daisuke; Hoda,Mir Alireza; Matsumoto,Isao; Klepetko,Walter; Oda,Makoto; Yano,Seiji; Watanabe,Go

doi:10.3892/or.2013.2948

Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma

Authors:
- Makio Moriya
- Tadaaki Yamada
- Masaya Tamura
- Daisuke Ishikawa
- Mir Alireza Hoda
- Isao Matsumoto
- Walter Klepetko
- Makoto Oda
- Seiji Yano
- Go Watanabe
View Affiliations

Affiliations: Department of General and Cardiothoracic Surgery, Kanazawa University, Kanazawa, Japan, Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan, Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria
Published online on: December 30, 2013 https://doi.org/10.3892/or.2013.2948
Pages: 1109-1115

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The mTOR inhibitor temsirolimus has antitumor and antiangiogenic activity against several carcinomas, yet few reports document the efficacy of temsirolimus against malignant pleural mesothelioma (MPM). Therefore, we evaluated the efficacy of temsirolimus and the antiangiogenic effect of temsirolimus in the treatment of MPM. We examined the efficacy of temsirolimus alone and the efficacy of the combination of temsirolimus and cisplatin or pemetrexed against four MPM cell lines using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. The effect of temsirolimus on the production of proangiogenic cytokines by MPM cell lines was examined by enzyme-linked immunosorbent assay (ELISA). Expression of mTOR and proangiogenic cytokines in clinical specimens from MPM patients was determined by immunohistochemistry. Temsirolimus inhibited cell viability and suppressed cell proliferation of all MPM cell lines. Combined treatment with temsirolimus and cisplatin inhibited the viability of all MPM cell lines more effectively than temsirolimus alone. Temsirolimus strongly inhibited the phosphorylation of p70s6k, a downstream molecule of mTOR, in all MPM cell lines and led to an increase in the levels of cleaved caspase-3 in the H226 and Y-meso14 cells. Temsirolimus also inhibited the production of vascular endothelial growth factor (VEGF) and platelet-derived growth factor-AA (PDGF-AA). Phosphorylated mTOR and high expression of VEGF and PDGF were detected in 2 and 3, respectively, out of the 5 MPM specimens. These results suggest that temsirolimus has activity against MPM cells by inhibition of cell proliferation and angiogenesis, and may be beneficial for a subset of MPM patients with high mTOR expression.

View Figures

View References

1	Ong ST and Vogelzang NJ: Chemotherapy in malignant pleural mesothelioma. A review. J Clin Oncol. 14:1007–1017. 1996.PubMed/NCBI
2	Antman KH: Natural history and epidemiology of malignant mesothelioma. Chest. 103:373S–376S. 1993. View Article : Google Scholar : PubMed/NCBI
3	Aisner J: Current approach to malignant mesothelioma of the pleura. Chest. 107:332S–344S. 1995. View Article : Google Scholar : PubMed/NCBI
4	Schmelzle T and Hall MN: TOR, a central controller of cell growth. Cell. 103:253–262. 2000. View Article : Google Scholar : PubMed/NCBI
5	Grewe M, Gansauge F, Schmid RM, Adler G and Seufferlein T: Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res. 59:3581–3587. 1999.PubMed/NCBI
6	Del Bufalo D, Ciuffreda L, Trisciuoglio D, et al: Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res. 66:5549–5554. 2006.PubMed/NCBI
7	Hudes G, Carducci M, Tomczak P, et al: Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 356:2271–2281. 2007. View Article : Google Scholar
8	Chan S, Scheulen ME, Johnston S, et al: Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol. 23:5314–5322. 2005. View Article : Google Scholar : PubMed/NCBI
9	Hartman ML, Esposito JM, Yeap BY and Sugarbaker DJ: Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma. J Thorac Cardiovasc Surg. 5:1233–1240. 2010. View Article : Google Scholar : PubMed/NCBI
10	Hoda MA, Mohamed A, Ghanim B, et al: Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy. J Thorac Oncol. 6:852–863. 2011. View Article : Google Scholar : PubMed/NCBI
11	Frost P, Moatamed F, Hoang B, et al: In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood. 15:4181–4187. 2004. View Article : Google Scholar : PubMed/NCBI
12	Green LM, Reade JL and Ware CF: Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines. J Immunol Methods. 70:257–268. 1984. View Article : Google Scholar : PubMed/NCBI
13	Dobashi Y, Suzuki S, Sato E, Hamada Y, Yanagawa T and Ooi A: EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors. Mod Pathol. 22:1328–1340. 2009. View Article : Google Scholar : PubMed/NCBI
14	Galanis E, Buckner JC, Maurer MJ, et al: Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol. 23:5294–5304. 2005. View Article : Google Scholar : PubMed/NCBI
15	Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB and Thomas G: Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k. EMBO J. 16:3693–3704. 1997.
16	Schedel F, Pries R, Thode B, et al: mTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma. Oncol Rep. 25:763–768. 2011.
17	Vogelzang NJ, Rusthoven JJ, Symanowski J, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 21:2636–2644. 2003. View Article : Google Scholar : PubMed/NCBI
18	Fidler IJ and Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell. 79:185–188. 1994. View Article : Google Scholar : PubMed/NCBI
19	Niedergethmann M, Hildenbrand R, Wostbrock B, et al: High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas. 25:122–129. 2002. View Article : Google Scholar
20	Takahashi Y, Kitadai Y, Bucana CD, Cleary KR and Ellis LM: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 55:3964–3968. 1995.PubMed/NCBI
21	Ostman A and Heldin CH: PDGF receptors as targets in tumor treatment. Adv Cancer Res. 97:247–274. 2007. View Article : Google Scholar : PubMed/NCBI
22	Andrae J, Gallini R and Betsholtz C: Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 22:1276–1312. 2008. View Article : Google Scholar : PubMed/NCBI
23	Guba M, Yezhelyev M, Eichhorn ME, et al: Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. Blood. 105:4463–4469. 2005. View Article : Google Scholar : PubMed/NCBI
24	Li Q, Yano S, Ogino H, et al: The therapeutic efficacy of anti-vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. Clin Cancer Res. 13:5918–5925. 2007. View Article : Google Scholar
25	Ikuta K, Yano S, Trung VT, et al: E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles. Clin Cancer Res. 15:7229–7237. 2009. View Article : Google Scholar